Article Details
Retrieved on: 2018-02-26 20:22:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Their work provided the scientific foundation for a new immuno-oncology startup fostered by Versant Ventures and <b>Polaris Partners</b> in 2016. And now their biotech, Quentis Therapeutics, is debuting with a $48 million A round with plans to get into the clinic next year. Michael Aberman, who left his job as ...</div>
Article found on:
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here